1. Heartland Virus Disease—An Underreported Emerging Infection.
- Author
-
Dembek, Zygmunt F., Mothershead, Jerry L., Cirimotich, Christopher M., and Wu, Aiguo
- Subjects
EMERGING infectious diseases ,VIRUS diseases ,ANIMAL populations ,APPETITE loss ,TICK infestations ,CLINICAL deterioration - Abstract
Simple Summary: Heartland virus is an underrecognized emerging viral disease with potentially serious sequelae. The tick vector that transmits this disease, A. americanum, continues to expand to states and regions in the US where it was previously undocumented. This geographic expansion is stimulated by increasingly favorable climatic conditions and increasing numbers of host animal populations upon which the tick can feed. More work needs to be conducted to identify all aspects of the natural transmission cycle for HRTV. The true human population burden of Heartland virus is unknown, as comprehensive state, regional and national serosurveys have not been conducted. Expanded HRTV disease surveillance is needed. The absence of commercially available rapid and accurate HRTV tests dictates that the burden of testing remains with the CDC. Given the absence of antiviral treatment for Heartland virus disease, rest, fluids and OTC medications are most often used to treat patients, with hospital-provided IV fluids and supportive care for serious cases. Potential but unused treatments for HRTV infections include favipiravir, tanshinone I and IIa, anidulafungin and the NF-κB inhibitor SC75741, with anidulafungin potentially available for 'off-label' use for serious illness. Developmental research to create vaccines for SFTSV and HRTV suggests that vaccines might one day become available for prevention against HRTV infections. First recognized 15 years ago, Heartland virus disease (Heartland) is a tickborne infection contracted from the transmission of Heartland virus (HRTV) through tick bites from the lone star tick (Amblyomma americanum) and potentially other tick species. Heartland symptoms include a fever <100.4 °F, lethargy, fatigue, headaches, myalgia, a loss of appetite, nausea, diarrhea, weight loss, arthralgia, leukopenia and thrombocytopenia. We reviewed the existing peer-reviewed literature for HRTV and Heartland to more completely characterize this rarely reported, recently discovered illness. The absence of ongoing serosurveys and targeted clinical and tickborne virus investigations specific to HRTV presence and Heartland likely contributes to infection underestimation. While HRTV transmission occurs in southern and midwestern states, the true range of this infection is likely larger than now understood. The disease's proliferation benefits from an expanded tick range due to rising climate temperatures favoring habitat expansion. We recommend HRTV disease be considered in the differential diagnosis for patients with a reported exposure to ticks in areas where HRTV has been previously identified. HRTV testing should be considered early for those matching the Heartland disease profile and nonresponsive to initial broad-spectrum antimicrobial treatment. Despite aggressive supportive therapy, patients deteriorating to sepsis early in the course of the disease have a very grim prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF